logo

ENLV

Enlivex TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ENLV Profile

Enlivex Therapeutics Ltd.

A clinical-stage macrophage reprogramming immunotherapy company

Pharmaceutical
01/22/2012
07/31/2014
NASDAQ Stock Exchange
36
12-31
Common stock
14 Einstein Street, Ness-Ziona, Israel 7403618
Focus on identifying, licensing, acquiring, developing and marketing drugs for the treatment of rare and rare genetic diseases.
Enlivex Therapeutics Ltd., an Israeli company headquartered in Tel Aviv, was established on January 22, 2012. The company is a still developing biopharmaceutical company focused on identifying, licensing, acquiring, developing and marketing drugs for the treatment of rare and rare genetic diseases. The company seeks a solution that identifies the pathophysiological mechanisms common to several diseases included. The company focuses on the manifestations of rare diseases, has clear medical needs, and the biological mechanisms of action are well known, and there is no satisfactory treatment for them.